Recombinant Human sTNF RI/TNFRSF1A (Recombinant Human soluble Tumor Necrosis Factor Receptor Type I/TNFRSF1A; rHusTNF RI/TNFRSF1A)；重组人可溶性肿瘤坏死因子受体I型/TNFRSF1A
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-alpha mediated cytotoxicity in the L-929 cells is less than 0.05μg/ml, corresponding to a specific activity of >2×104IU/mg in the presence of 0.25ng/ml of rHuTNF-alpha.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered solution in PBS, pH7.4.
Endotoxin
Less than 0.1EU/μg of rHusTNF RI/TNFRSF1A as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
TNF RI, also named as TNFR-I, TNF R1, TNFRSF1A, p55 and p60, belongs to the tumor necrosis factor receptor superfamily, and it is encoded by the TNFRSF1A gene in human. TNF RI is a universally expressed protein and is thought to form homotrimers after ligand binding. TNF RI is one of the major receptors for the TNF-α. This receptor can activate the transcription factor NF-κB, mediate apoptosis, and function as a regulator of inflammation. Mature human soluble TNF RI shares 68%~73% amino acid sequence identity with murine, rat, bovine and porcine soluble TNF RI.
